Replies to post #36957 on Amarin Corp Plc (AMRN)

[sts66]

As of my last lipid panel I'm now on-label, not off - had nothing to do with Aetna putting V back onto T4 in any case, it was a pure cost cutting action to save a few bucks/patient and force them onto generic L, which is absolutely not an option for me because of other health issues.

[BioChica]

That is wishful thinking, but they can not plan on a maybe. Taking the conservative approach to sales will take to long, I think they need to expand their Marketing/Sales force, perhaps even change the current method of marketing. The one they are using just is not working well. In other words we need a new marketing strategy.

I have seen T.V. Ads for drugs recently approved! Do we have any?
I think making patients aware of a drug like ours, will work. Patients can have an effect on physicians. I know I did, and many others here have had the same experience!

Regarding insurance coverage, just because STS66 insurance coverage move to a higher tier is meaningless, more insurance companies have moved to tier two, and no special requirement.

I hope we see an early completion on RI results, it may happen. But lets say by mid 2016 we are looking at minimal sales, no indication that REDUCE-IT is being stopped. Since we marketed Vascepa for a small market share, the market you suggest they focus on, will lead to small script numbers, low income, low PPS!